COVID-19.рф: ИНФОРМАЦИЯ ПРОТИВ ПАНДЕМИИ

Поиск по репозиторию

Статья

Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study

R. Bain, R. Cosgriff, M. Zampoli, A. Elbert, P. Burgel, S. Carr, C. Castaños, C. Colombo, H. Corvol, A. Faro, C. Goss, H. Gutierrez, A. Jung, N. Kashirskaya, B. Marshall, J. Melo, P. Mondejar-Lopez, M. de, L. Naehrlich, R. Padoan, M. Pastor-Vivero, S. Rizvi, M. Salvatore, L. Filho, K. Brownlee, I. Haq, M. Brodlie,
2021
https://doi.org/10.1016/j.jcf.2020.11.021

Background: The presence of co-morbidities, including underlying respiratory problems, has been identified as a risk factor for severe COVID-19 disease. Information on the clinical course of SARS-CoV-2 infection in children with cystic fibrosis (CF) is limited, yet vital to provide accurate advice for children with CF, their families, caregivers and clinical teams. Methods: Cases of SARS-CoV-2 infection in children with CF aged less than 18 years were collated by the CF Registry Global Harmonization Group across 13 countries between 1 February and 7 August 2020. Results: Data on 105 children were collated and analysed. Median age of cases was ten years (interquartile range 6–15), 54% were male and median percentage predicted forced expiratory volume in one second was 94% (interquartile range 79–104). The majority (71%) of children were managed in the community during their COVID-19 illness. Out of 24 children admitted to hospital, six required supplementary oxygen and two non-invasive ventilation. Around half were prescribed antibiotics, five children received antiviral treatments, four azithromycin and one additional corticosteroids. Children that were hospitalised had lower lung function and reduced body mass index Z-scores. One child died six weeks after testing positive for SARS-CoV-2 following a deterioration that was not attributed to COVID-19 disease. Conclusions: SARS-CoV-2 infection in children with CF is usually associated with a mild illness in those who do not have pre-existing severe lung disease. © 2020

Цитирование

Похожие публикации

The global impact of SARS-CoV-2 in 181 people with cystic fibrosis
E. McClenaghan, R. Cosgriff, K. Brownlee,
Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020
N. Lutz, O. Annalisa, D. Fiona,
Coronavirus infection (Covid-19) in children with cystic fibrosis
E. Kondratyeva, V. Sherman, E. Zhekaite,

Документы

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • R. Bain
    Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
  • R. Cosgriff
    Cystic Fibrosis Trust, London, United Kingdom
  • M. Zampoli
    Division of Paediatric Pulmonology, Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, University of Cape Town, South Africa
  • A. Elbert
    Cystic Fibrosis Foundation, Bethesda, MD, United States
  • P. Burgel
    Respiratory Medicine and National Reference CF Center, AP-HP Hôpital Cochin, Paris, France
  • S. Carr
    Université de Paris, Institut Cochin, Inserm U-1016, Paris, France
  • C. Castaños
    Royal Brompton Hospital and Imperial College, London, United Kingdom
  • C. Colombo
    Department of Pulmonology, Hospital de Pediatria JP Garrahan, Buenos Aires, Argentina
  • H. Corvol
    CF Regional Reference Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Italy
  • A. Faro
    Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, Assistance Publique Hôpitaux de Paris (APHP), Hôpital Trousseau, Service de Pneumologie Pédiatrique, Paris, France
  • C. Goss
    Department of Medicine and Pediatrics, University of Washington, Seattle, WA, United States
  • H. Gutierrez
    Pediatric Pulmonary and Sleep Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States
  • A. Jung
    Department of Pulmonology and Children's Research Centre, University Children's Hospital Zurich, Zurich, Switzerland
  • N. Kashirskaya
    Laboratory of Genetic Epidemiology, Research Centre for Medical Genetics, Moscow, Russian Federation
  • B. Marshall
    Instituo Nacional del Tórax, Santiago, Chile
  • J. Melo
    Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain
  • P. Mondejar-Lopez
    Stockholm Cystic Fibrosis Centre Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
  • M. de
    Universities of Giessen and Marburg Lung Center, German Center of Lung Research, Justus‐Liebig‐University Giessen, Giessen, Germany
  • L. Naehrlich
    Pediatric Pulmonology and Cystic Fibrosis Unit, Osakidetza, Hospital Universitario Cruces, Barakado, Bizkaia, Spain
  • R. Padoan
    Pediatric Pulmonology Unit, Instituto da Criança do Hospital das Clínicas da FMUSP, São Paulo, São Paulo, Brazil
  • M. Pastor-Vivero
    Paediatric Respiratory Medicine, Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
  • S. Rizvi
    Cystic Fibrosis Support Center, Department of Paediatric, University of Brescia, Italy
  • M. Salvatore
    National Center Rare Diseases, Undiagnosed Rare Diseases Interdepartmental Unit Istituto Superiore di Sanità, Rome, Italy
  • L. Filho
  • K. Brownlee
  • I. Haq
  • M. Brodlie
Название журнала
  • Journal of Cystic Fibrosis
Том
  • 20
Выпуск
  • 1
Страницы
  • 25-30
Ключевые слова
  • adolescent; child; clinical trial; complication; cystic fibrosis; disease exacerbation; female; human; male; multicenter study; prognosis; risk factor; Adolescent; Child; COVID-19; Cystic Fibrosis; Disease Progression; Female; Humans; Male; Prognosis; Risk Factors; SARS-CoV-2
Издатель
  • Elsevier B.V.
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus
COVID-19.рф: Информация против пандемии

Адрес: 115114, Москва, ул. Летниковская, д. 4, стр.5, офис 2.4
тел.\факс: +7(499)754-99-94, доб. 502
e-mail: covid19@neicon.ru

Проект реализуется с использованием гранта Президента Российской Федерации на развитие гражданского общества, предоставленного Фондом президентских грантов.

Содержимое сайта, если не указано иное, опубликовано в соответствии с лицензией Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная (CC BY 4.0). Права на материалы, переданные партнерами проекта, принадлежат их правообладателям.

© 2025 NEICON